Latest Roswell Park Cancer Institute Stories
Dr. Brian G.M. Durie, co-founder and chair of the International Myeloma Foundation (IMF), heads consortium of investigators across U.S. LOS ANGELES, April 12 /PRNewswire-USNewswire/ -- Aptium Oncology, Inc.
Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.
DETROIT, Jan. 29 /PRNewswire-USNewswire/ -- After a 10-month nationwide search, Gerold Bepler, M.D., Ph.D., has been named the new president and chief executive officer of the Barbara Ann Karmanos Cancer Institute. A thoracic oncologist, Dr. Bepler will begin his new position Feb. 1, 2010.
NCCN updates the NCCN Guidelines for Non-Small Cell Lung Cancer to include guidance on maintenance therapy, several new therapeutic recommendations for specific patients with Non-Small Cell Lung Cancer, and a revised staging system. FORT WASHINGTON, Pa., Dec.
SOUTHBRIDGE, Mass., Dec.
Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). FORT WASHINGTON, Pa., Nov.
NCCN program on Discovery Health Channel profiles patients undergoing treatment for metastatic breast cancer and their physicians' use of the NCCN Clinical Practice Guidelines in Oncology(TM) for Breast Cancer to determine an individualized treatment regimen.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors.
The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma.
Although colonoscopy remains the preferred colorectal cancer screening method, the recently updated NCCN Guidelines for Colorectal Cancer Screening have added annual immunohistochemical stool testing with or without a flexible sigmoidoscopy every five years as an alternate screening option for average risk individuals.
- A transitional zone between two communities containing the characteristic species of each.